Investors Thursday drove shares of Keryx Biopharmaceuticals Inc. up 6.8 percent after the firm said it started a short-term Phase III study evaluating Zerenex (ferric citrate), an iron-based phosphate binder, as a treatment for hyperphosphatemia in dialysis patients with end-stage renal disease (ESRD). (BioWorld Today)